12:00 AM
 | 
Jul 19, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/16 cls
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Rodman Elemer Piros Downgrade Underperform (from market perform) 21% $4.66
Piros also set a $1 target after FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-6 that the benefit-risk profile for competitor compound Qnexa phentermine/topiramate from Vivus Inc. (NASDAQ:VVUS) did not support approval to treat obesity. Piros believes Arena's lorcaserin, a serotonin (5-HT2C) receptor agonist for obesity, is likely to present regulatory challenges due to a limited safety database and its weak efficacy. Lorcaserin has an Oct. 22 PDUFA date (see "FDA's Weight Problem," A2).
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) Brean Murray Jonathan Aschoff Price target Sell

Read the full 767 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >